Participants will be randomly selected to receive daily either 1) 20mg of study medication, or 2) inactive placebo. Participants will meet with the research team every 2 weeks (or via telephone call) and will complete questionnaires and computerised tasks to assess symptoms, attention, and thinking skills. Following completion of the trial, participants will meet with the Chief Investigator, Professor Jayashri Kulkarni, to discuss their results and any further treatment recommendation.
Miss Raelene Tan
Contact phone number: (03) 9076 5031
Ethics Committee Project Number: 204/14